Physicochemical, nutritional and in vitro antidiabetic characterisation of blue whiting (micromesistius poutassou) protein hydrolysates by Harnedy-Rothwell, Pádraigín A. et al.
marine drugs 
Article
Physicochemical, Nutritional and In Vitro Antidiabetic
Characterisation of Blue Whiting (Micromesistius poutassou)
Protein Hydrolysates
Pádraigín A Harnedy-Rothwell 1,2 , Neda Khatib 1, Shaun Sharkey 3, Ryan A Lafferty 3, Snehal Gite 4,




Khatib, N.; Sharkey, S.; Lafferty, R.A.;
Gite, S.; Whooley, J.; O’Harte, F.P.M.;
FitzGerald, R.J. Physicochemical,
Nutritional and In Vitro Antidiabetic
Characterisation of Blue Whiting
(Micromesistius poutassou) Protein
Hydrolysates. Mar. Drugs 2021, 19,
383. https://doi.org/10.3390/
md19070383
Academic Editors: Concetta Messina
and Andrea Santulli
Received: 31 May 2021
Accepted: 30 June 2021
Published: 2 July 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 Department of Biological Sciences, University of Limerick, V94 T9PX Limerick, Ireland;
padraigin.harnedy@ul.ie (P.A.H.-R.); neda.khatib@ul.ie (N.K.)
2 Health Research Institute, University of Limerick, V94 T9PX Limerick, Ireland
3 School of Biomedical Sciences, Ulster University, Coleraine BT52 1SA, UK; Sharkey-S5@ulster.ac.uk (S.S.);
r.lafferty@ulster.ac.uk (R.A.L.); fpm.oharte@ulster.ac.uk (F.P.M.O.)
4 Bio-Marine Ingredients Ireland Ltd., Lough Egish Food Park, A75 WR82 Castleblaney, Ireland;
snehal@biomarine.ie (S.G.); jason@biomarine.ie (J.W.)
* Correspondence: dick.fitzgerald@ul.ie
Abstract: Protein hydrolysates from low-value underutilised fish species are potential sources of high-
quality dietary protein and health enhancing peptides. Six blue whiting soluble protein hydrolysates
(BW-SPH-A_F), generated at industrial scale using different hydrolysis conditions, were assessed
in terms of their protein equivalent content, amino acid profile and score and physicochemical
properties in addition to their ability to inhibit dipeptidyl peptidase IV (DPP-IV) and stimulate the
secretion of insulin from BRIN-BD11 cells. Furthermore, the effect of simulated gastrointestinal
digestion (SGID) on the stability of the BW-SPHs and their associated in vitro antidiabetic activity
was investigated. The BW-SPHs contained between 70–74% (w/w) protein and all essential and non-
essential amino acids. All BW-SPHs mediated DPP-IV inhibitory (IC50: 2.12–2.90 mg protein/mL)
and insulin secretory activity (2.5 mg/mL; 4.7 to 6.4-fold increase compared to the basal control
(5.6 mM glucose alone)). All BW-SPHs were further hydrolysed during SGID. While the in vitro
DPP-IV inhibitory and insulin secretory activity mediated by some BW-SPHs was reduced following
SGID, the activity remained high. In general, the insulin secretory activity of the BW-SPHs were
4.5–5.4-fold higher than the basal control following SGID. The BW-SPHs generated herein provide
potential for anti-diabetic related functional ingredients, whilst also enhancing environmental and
commercial sustainability.
Keywords: blue whiting; protein hydrolysate; antidiabetic; type 2 diabetes mellitus; insulinotropic;
functional food; amino acid analysis
1. Introduction
Fishery resources are an excellent source of high-quality dietary protein. In general,
fish meat contains between 17% and 22% (w/w) protein which is readily digestible and
contains all essential amino acids in quantities that meet human dietary requirements [1,2].
Reports indicate that fish consumption per capita globally in 2016 was 19.7 kg, which
equated to approximately 17.40% of the population’s intake of animal protein worldwide
and approximately 6.90% of all proteins consumed [3]. However, emerging trends show
an increased consumer demand in the developed world for fish-based proteins, among
others, which are perceived to be healthier than terrestrial animal derived equivalents.
Furthermore, with the global demand for high-quality protein rapidly increasing and
the over-stretched land-based resources, emerging proteins derived from non-land based
sources will be a key component and driver of food companies’ future business strategies.
However, there is a growing need to increase sustainable practices within the marine sector.
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Fish stocks are limited and in order to assist in the protection of fisheries resources for
future utilisation, annual total allowable catches (TACs) and quota allocations have been
reduced over the past decade in response to growing concerns over the overutilization
of numerous fish stocks [4]. Furthermore, with the landing obligation strategy of the
European Common Fisheries Policy (CFP Art. 15) implemented in full across the EU in
2019, commercial fisheries have been forced to land all species caught including those that
do not reach a minimum legal size or those subjected to quota. As a result, the marine
industry has been forced to investigate more innovative and sustainable ways of increasing
the value of all fish caught and landed [5].
Blue whiting (Micromesistius poutassou) is one of the most abundant fish stocks landed
in the Northeast Atlantic in recent years. To date, most of the catch is reduced to fishmeal
or used for fish oil as there is little or no demand for its human consumption. However,
this low-value underutilized species is a rich source of high-quality protein (16.5% (w/w))
and utilization of such a resource could offer a sustainable alternative to meet the ever-
increasing global protein demand, in addition to adding value to this landed resource [6].
The value can be further increased through the exploitation of blue whiting as a source of
high-value health enhancing peptide ingredients for human food applications. Enzymatic
hydrolysates of blue whiting proteins have shown health enhancing properties both in vitro
and in vivo, in particular in the beneficial regulation of satiety and glycaemia [6–10].
Bioavailable peptides derived from this resource may be useful as natural alternatives,
used alone or in combination with reduced doses of conventional synthetic drugs, to aid
in the prevention and management of the growing prevalence of the chronic metabolic
condition, Type 2 diabetes mellitus (T2DM).
One of the many challenges that exist for exploitation of fish as sources of functional
ingredients is in the reproducible production of products on an industrial scale which are
clean flavoured, white coloured and odour free. However, recent advances in processing
technologies, in particular innovative green technologies such as ultrasound-assisted- and
supercritical fluid-extraction and the availability of enzyme preparations with specific
activities for enzyme assisted extraction, aid in addressing such challenges. In this study
six blue whiting soluble protein hydrolysates (BW-SPHs), generated at industrial scale
using different hydrolysis conditions, were assessed in terms of their protein equivalent
content, amino acid profile and score, physicochemical properties, and for their ability to
inhibit dipeptidyl peptidase IV (DPP-IV) and to stimulate the secretion of insulin from
pancreatic BRIN-BD11 β-cells grown in culture. Furthermore, the effect of simulated
gastrointestinal digestion (SGID) on the stability of the six hydrolysates and their associated
in vitro antidiabetic activity was investigated.
2. Results
2.1. Protein and Amino Acid Analysis of BW-SPH-A_F
The nitrogen content of the samples ranged from 13.76% to 14.45% (w/w) and using
sample specific nitrogen to protein (N:P) conversion factors (5.04 to 5.24) all six BW-SPHs
(BW-SPH-A_F) generated at industrial scale were shown to have high protein equiva-
lent contents ranging from 70.37% to 73.60% (w/w) (Table 1). The lipid content of the
hydrolysates was negligible at ≤0.5% (w/w, data not shown).
In general, the total amino acid profiles of all six BW-SPHs were similar (Table 2). All
six hydrolysates contained all the essential and non-essential amino acids. The amino acids
found in highest abundance in all hydrolysates include Glx (combined glutamic acid and
glutamine) and Asx (combined aspartic acid and asparagine) which ranged from 12.00 to
12.90 and 8.10 to 8.56 g/100 g, respectively. Amino acids found in least abundance in all
hydrolysates include cysteine and tryptophan which ranged from 0.57 to 0.61 and 0.45 to
0.59 g/100 g, respectively. Hydroxyproline levels of 0.79, 0.76, 0.87, 0.61 0.79 and 0.88%
(w/w), which is derived from collagen components were found in samples BW-SPH-A,
BW-SPH-B, BW-SPH-C, BW-SPH-D, BW-SPH-E and BW-SPH-F, respectively (Table 2).
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Table 1. Total nitrogen content, nitrogen to protein (N:P) conversion factors and protein content of
blue whiting (Micromesistius poutassou) soluble protein hydrolysates (BW-SPHs).





BW-SPH-A 14.05 ± 0.10 5.24 73.60 ± 0.53
BW-SPH-B 13.92 ± 0.05 5.19 72.24 ± 0.24
BW-SPH-C 14.45 ± 0.16 5.04 72.77 ± 0.80
BW-SPH-D 13.76 ± 0.06 5.12 70.37 ± 0.33
BW-SPH-E 13.87 ± 0.03 5.12 71.02 ± 0.14
BW-SPH-F 14.20 ± 0.06 5.15 73.03 ± 0.30
Mean ± SD (n = 3).
The free amino acid profiles of the six BW-SPHs were different (Table 2). As expected,
samples BW-SPH-A, BW-SPH-B and BW-SPH-E, which had the greatest extents of hydroly-
sis and highest quantities of components <1 kDa, contained higher quantities of free amino
acids compared to BW-SPH-C, BW-SPH-D and BW-SPH-F, which had lower degree of
hydrolysis (DH) values (Tables 2 and 3). While BW-SPH-A, BW-SPH-B and BW-SPH-E
were generated using similar hydrolysis conditions, except for the second enzyme in the
two-enzyme combination and had similar DH values, their free amino acid profile varied
(Tables 2–4). In particular, BW-SPH-E had a lower level of free lysine at 0.31% (w/w) com-
pared to BW-SPH-A and BW-SPH-B which had levels of 2.15 and 1.98% (w/w), respectively
(Table 2). BW-SPH-A was shown to have lower levels of free isoleucine compared to the
other two samples while BW-SPH-B was shown to have higher levels of free cysteine
compared to BW-SPH-A and BW-SPH-E (Table 2). These differences in free amino acid
profiles are most likely due to the specificity of the second enzyme preparation used for
the generation of the three samples. In general, the free amino acid residues found in lower
abundance in BW-SPH-C, BW-SPH-D and BW-SPH-F compared to BW-SPH-A, BW-SPH-
B and BW-SPH-E include serine, Glx, valine, isoleucine, methionine and phenylalanine
(Table 2). The levels of free glycine and histidine were approximately 22% and 45–65%,
respectively, and was lower in BW-SPH-C compared to all other BW-SPH samples (Table 2).
Furthermore, the level of free lysine in BW-SPH-C was approximately 80–90% lower than
that observed in BW-SPH-A, BW-SPH-B, BW-SPH-D and BW-SPH-F.
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Table 2. Total (TAA) and free amino acid (FAA) profiles of blue whiting (Micromesistius poutassou) soluble protein hydrolysates (BW-SPHs) pre- and post-simulated gastrointestinal
digestion (GI).
BW-SPH-A BW-SPH-B BW-SPH-C BW-SPH-D BW-SPH-E BW-SPH-F
TAA FAA FAA-GI TAA FAA FAA-GI TAA FAA FAA-GI TAA FAA FAA-GI TAA FAA FAA-GI TAA FAA FAA-GI
Asx 8.56 0.31 0.33 8.45 0.37 0.37 8.31 0.25 0.21 8.10 0.18 0.18 8.13 0.40 0.38 8.52 0.30 0.28
Ser 4.10 0.91 0.88 4.04 0.75 0.76 4.07 0.45 0.45 4.00 0.40 0.42 3.93 0.82 0.85 4.07 0.53 0.55
Glx 12.50 1.02 1.11 12.60 0.90 1.03 12.80 0.65 0.68 12.00 0.52 0.62 12.40 0.84 0.98 12.90 0.65 0.70
Gly 5.52 0.22 0.26 5.43 0.23 0.28 5.85 0.16 0.18 5.10 0.21 0.25 5.55 0.23 0.30 5.85 0.21 0.24
Arg 5.94 2.48 3.92 6.15 2.45 3.99 6.31 2.08 3.86 6.15 1.94 3.48 6.31 2.54 2.77 6.34 1.97 3.78
Pro 3.41 <0.050 <0.005 3.30 <0.050 <0.005 3.31 <0.050 <0.005 3.14 <0.050 <0.005 3.33 <0.050 <0.005 3.49 <0.050 <0.005
Ala 5.41 0.82 0.86 5.54 0.79 0.81 5.71 0.63 0.62 5.28 0.49 0.56 5.30 0.81 0.88 5.53 0.68 0.68
Cys 0.61 nd nd 0.61 0.63 nd 0.59 0.41 nd 0.60 0.58 nd 0.57 0.23 nd 0.57 nd nd
Tyr 3.23 0.82 2.06 2.37 0.66 1.42 2.04 0.44 1.68 2.47 0.46 1.70 2.25 0.81 1.75 2.31 0.60 1.61
Hyp 0.79 - - 0.76 - - 0.87 - - 0.61 - - 0.79 - - 0.88 - -
Val 3.89 0.97 0.81 3.81 1.12 0.99 3.39 0.42 0.41 3.50 0.43 0.34 3.70 1.22 1.09 3.57 0.65 0.60
Ile 3.35 0.85 0.95 3.34 1.17 1.23 2.78 0.39 0.45 2.96 0.48 0.39 3.32 1.25 1.33 3.05 0.66 0.85
Leu 5.78 2.71 2.88 5.63 3.08 3.08 5.49 1.28 2.00 5.51 1.62 1.88 5.40 3.41 3.50 5.61 2.21 2.49
Thr 3.70 0.91 0.98 3.57 0.89 1.01 3.41 0.72 0.72 3.38 0.57 0.59 3.43 0.95 1.19 3.58 0.72 0.96
Met 1.94 1.02 1.01 1.76 0.87 0.92 1.79 0.49 0.71 1.93 0.60 0.78 1.65 0.91 1.03 1.79 0.67 0.83
Lys 7.44 2.15 3.53 7.65 1.98 3.38 7.48 0.19 2.61 7.35 0.94 2.95 7.48 0.31 3.37 7.54 1.13 3.21
His 1.53 0.30 0.48 1.55 0.25 0.45 1.46 0.10 0.41 1.56 0.19 0.38 1.46 0.29 0.57 1.60 0.22 0.46
Phe 2.87 1.46 1.63 2.80 1.26 1.50 2.54 0.64 1.16 2.74 0.80 1.18 2.50 1.37 1.52 2.55 1.00 1.30
Trp 0.56 0.18 0.20 0.58 0.15 0.16 0.45 0.06 0.10 0.59 0.11 0.14 0.50 0.16 0.17 0.57 0.11 0.17
ΣEAAs 31.06 10.55 12.47 30.69 10.77 12.71 28.79 4.28 8.56 29.52 5.74 8.64 29.44 9.87 13.75 29.86 7.36 10.88
ΣAAs 81.03 17.13 21.87 79.94 17.55 21.37 78.65 9.34 16.24 76.97 10.52 15.85 78.00 16.54 21.68 80.32 12.31 18.73
Amino acid residues are denoted by their 3-letter code. Asx: Aspartic acid and asparagine, Glx: Glutamic acid and glutamine, EAAs: essential amino acids, nd: not detected, -: not determined.
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Table 3. Physicochemical properties of blue whiting (Micromesistius poutassou) soluble protein hydrolysates (BW-SPHs) pre-
and post-simulated gastrointestinal digestion (GI).
Sample Code Degree ofHydrolysis (DH%)
Molecular Mass Distribution (%)
>10 kDa 5–10 kDa 2–5 kDa 1–2 kDa <1 kDa
BW-SPH-A 43.19 ± 2.16 a 0.32 ± 0.08 1.47 ± 0.08 6.26 ± 0.04 14.11 ± 0.01 77.86 ± 0.16
BW-SPH-A_GI 57.48 ± 2.72 AB* 0.00 ± 0.00 0.04 ± 0.06 1.22 ± 0.02 6.88 ± 0.23 91.87 ± 0.30
BW-SPH-B 45.78 ± 2.91 a 0.99 ± 0.04 2.79 ± 0.03 9.10 ± 0.15 15.94 ± 0.12 71.19 ± 0.33
BW-SPH-B_GI 61.51 ± 2.66 AB* 0.00 ± 0.00 0.13 ± 0.03 1.82 ± 0.02 8.36 ± 0.02 89.70 ± 0.07
BW-SPH-C 27.82 ± 1.11 c 2.45 ± 0.05 5.56 ± 0.06 15.97 ± 0.07 20.48 ± 0.04 55.55 ± 0.13
BW-SPH-C_GI 55.37 ± 1.83 B* 0.00 ± 0.00 0.27 ± 0.01 2.77 ± 0.02 11.38 ± 0.03 85.58 ± 0.01
BW-SPH-D 36.59 ± 0.87 b 0.25 ± 0.05 1.49 ± 0.04 7.02 ± 0.03 16.67 ± 0.06 74.57 ± 0.08
BW-SPH-D_GI 56.13 ± 3.95 B* 0.00 ± 0.00 0.09 ± 0.03 1.35 ± 0.06 7.99 ± 0.02 90.58 ± 0.11
BW-SPH-E 42.97 ± 3.30 a 1.49 ± 0.02 3.31 ± 0.02 9.85 ± 0.05 15.62 ± 0.06 69.74 ± 0.13
BW-SPH-E_GI 65.23 ± 1.05 A* 0.00 ± 0.00 0.19 ± 0.04 2.03 ± 0.05 8.54 ± 0.09 89.54 ± 0.15
BW-SPH-F 36.53 ± 2.05 b 1.33 ± 0.02 3.71 ± 0.03 12.57 ± 0.06 19.45 ± 0.02 62.94 ± 0.11
BW-SPH-F_GI 57.90 ± 4.25 AB* 0.00 ± 0.00 0.24 ± 0.04 2.40 ± 0.07 10.02 ± 0.07 87.34 ± 0.18
Mean ± SD (n = 3). Different lower case letters (a,b,c) indicate a significant difference with BW-SPH samples pre-simulated gastrointestinal
digestion at p < 0.05. Different capital letters (A,B) indicate a significant difference with BW-SPH samples post- simulated gastrointestinal
digestion at p < 0.05. * indicates a significant difference at p < 0.05 between pre- and post-simulated gastrointestinal digestion values.
Table 4. Hydrolysis conditions used to generate blue whiting (Micromesistius poutassou) soluble











BW-SPH-A 2:1 1 and 2 0.169 and0.169 50 120
BW-SPH-B 2:1 2 and 3 0.169 and0.169 50 120
BW-SPH-C 1.7:1 4 and 5 0.005 and0.005 50 45
BW-SPH-D 1.7:1 4 and 5 0.900 and0.290 50 60
BW-SPH-E 2:1 2 and 6 0.169 and0.169 50 120
BW-SPH-F 2:1 7 0.340 50 120
(E:S) Enzyme to substrate ratio-weight of enzyme/weight of thawed minced fish.
As shown in Table 5 the calculated amino acid scores for the hydrolysates ranged from
0.36 to 0.49 when referenced against the recommended amino acid requirement pattern
for infants less than 6 months, with tryptophan identified as the limiting essential amino
acid in all samples [11]. For the additional two population cohorts (children from 6 months
to 3 years old and children >3 years old, adolescents and adults), tryptophan was also
identified as the limiting essential amino acid with amino acid scores ranging from 0.73 to
0.99 and 0.94 to 1.27 for these categories, respectively [11].
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Table 5. Calculated amino acid score for the blue whiting (Micromesistius poutassou) soluble protein hydrolysates (BW-SPH-
A_F) for different age categories.
Amino Acid BW-SPH-A BW-SPH-B BW-SPH-C BW-SPH-D BW-SPH-E BW-SPH-F
Amino acid ratio (infants (birth to 6 months))
SAA 1.05 0.99 0.99 1.09 0.95 0.98
Trp 0.45 * 0.47 * 0.36 * 0.49 * 0.41 * 0.46 *
Thr 1.14 1.12 1.06 1.09 1.10 1.11
Val 0.96 0.96 0.85 0.90 0.95 0.89
Ile 0.83 0.84 0.69 0.76 0.85 0.76
Leu 0.82 0.81 0.79 0.82 0.79 0.80
AAA 0.88 0.76 0.67 0.79 0.71 0.71
Lys 1.47 1.53 1.49 1.51 1.53 1.50
His 0.99 1.02 0.96 1.06 0.98 1.04
Amino acid ratio (child (6 months to 3 years))
SAA 1.28 1.22 1.21 1.33 1.16 1.20
Trp 0.90 * 0.94 * 0.73 * 0.99 * 0.83 * 0.92 *
Thr 1.62 1.59 1.51 1.55 1.56 1.58
Val 1.23 1.23 1.08 1.16 1.21 1.14
Ile 1.42 1.44 1.19 1.31 1.46 1.31
Leu 1.19 1.18 1.14 1.19 1.15 1.16
AAA 1.59 1.38 1.21 1.42 1.29 1.28
Lys 1.77 1.86 1.80 1.83 1.85 1.81
His 1.04 1.07 1.00 1.11 1.03 1.10
Amino acid ratio (older child, adolescent, adult)
SAA 1.51 1.43 1.42 1.56 1.36 1.41
Trp 1.15 * 1.22 * 0.94 * 1.27 * 1.07 * 1.18 *
Thr 2.01 1.98 1.87 1.92 1.93 1.96
Val 1.32 1.32 1.16 1.24 1.30 1.22
Ile 1.52 1.54 1.27 1.40 1.56 1.39
Leu 1.29 1.28 1.24 1.28 1.25 1.26
AAA 2.02 1.75 1.54 1.81 1.63 1.62
Lys 2.11 2.21 2.14 2.18 2.19 2.15
His 1.30 1.34 1.25 1.39 1.28 1.37
* Amino acid score (1st limiting amino acid), Amino acid residues are denoted by their 3-letter code. SAA: sulphur amino acids, AAA:
aromatic amino acids.
2.2. Physicochemical Properties of BW-SPHs Pre- and Post-Simulated Gastrointestinal Digestion
(SGID)
The different hydrolysis conditions employed during industrial generation, resulted
in BW-SPHs with varying DH. BW-SPH-A, BW-SPH-B, BW-SPH-E had significantly higher
DH values compared to all other samples (43.0–45.8%, Table 3, p < 0.05) with BW-SPH-C
having the lowest DH at 27.82 ± 1.11%. In general, the BW-SPHs showing high DHs
contained higher quantities of components <1 kDa (Table 3). As expected, BW-SPH-C, the
hydrolysate with the lowest DH had the lowest quantity of components in this molecular
mass category (55.55 ± 0.13%, <1 kDa) and 2.45 ± 0.05% of components >10 kDa (Table 3).
As stated previously, BW-SPH-A, BW-SPH-B and BW-SPH-E were generated using similar
hydrolysis conditions apart from the second enzyme in the two-enzyme combination
(Table 4). This may explain why all three samples had similar DH values and molecular
mass distribution profiles. Furthermore, the lower DH value and the level of components
<1 kDa observed for BW-SPH-C may be explained by the lower E:S (0.1% (w/w) minced
fish) and hydrolysis time (45 min) used to generate this hydrolysate compared to that
used for the generation of the other hydrolysates (E:S ≥ 0.338% (w/w) minced fish and an
hydrolysis time of ≥1 h, Tables 3 and 4).
Reversed phase-ultra-performance liquid chromatography (RP-UPLC) profiles demon-
strate that the retention times of the prominent peaks eluting between 0–8 min in all six
BW-SPHs were similar (Supplementary Figure S1). However, the intensity of these peaks,
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in addition to those eluting after 10 min, varied from one sample to the other. In particular,
the intensity of the peaks between 0–8 min were significantly lower in BW-SPH-C than
equivalent peaks in the other samples and specifically compared to those in BW-SPH-A,
BW-SPH-B and BW-SPH-F (Supplementary Figure S1). In contrast the intensity of the
peaks in the more hydrophobic region in particular at retention times >16 min are higher in
BW-SPH-C compared to the other samples. A unique peak was also observed in BW-SPH-C
at a retention time of 17.5 min. This may be associated with the lower extent of hydrolysis
observed in BW-SPH-C. Furthermore, a unique peak was also seen at 15 min in the peptide
profile of BW-SPH-F (Supplementary Figure S1).
The DH data, molecular mass distribution and RP-UPLC profiles show that all BW-
SPH were further degraded during SGID. A significant increase in DH was observed
following SGID (Table 3, p < 0.05) with the highest increase (approximately 27.5%) ob-
served with BW-SPH-C, the hydrolysate with the lowest DH pre-SGID. A corresponding
decrease in components >1 kDa and increase in components <1 kDa, was observed with all
hydrolysates (Table 3). Furthermore, on comparison of RP-UPLC peptide profiles pre- and
post-SGID significant differences were observed with all BW-SPH samples (Supplementary
Figure S1). Similarly to that observed between BW-SPH samples pre-SGID, distinct differ-
ences were observed in the RP-UPLC profiles of samples post-SGID (BW-SPH-A to F_GI).
The peak observed at a retention time of 15.0 min in the pre-SGID BW-SPH-F sample was
also observed, albeit at lower intensity, in the post SGID sample (Supplementary Figure S1).
2.3. Changes in Amino Acid Profile of the BW-SPHs as a Result of Simulated Gastrointestinal
Digestion (SGID)
The free amino acid content of all BW-SPHs, with the exception of valine, increased
following SGID. In particular, an increase in the level of free lysine, histidine, phenylalanine
and tyrosine was observed in all samples (Table 2). Interestingly, BW-SPH-C and BW-SPH-
E, which contained reduced levels of free lysine compared to the other BW-SPHs pre-SGID
contained lower or similar free lysine levels to all other BW-SPHs post-SGID (Table 2).
With the exception of BW-SPH-E, an increase in free arginine was observed in all BW-SPHs
following SGID.
2.4. DPP-IV Inhibitory Activity
BW-SPH-D was shown to mediate significantly higher DPP-IV inhibitory activity
(IC50: 2.12 ± 0.03 mg protein/mL, p < 0.05, Table 6) pre-SGID compared to all other BW-
SPHs. BW-SPH-C showed significantly lower DPP-IV inhibitory activity (IC50: 2.90 ± 0.07,
p < 0.05, Table 6) pre-SGID compared to all other BW-SPHs. A significant reduction in
DPP-IV inhibitory activity was observed following SGID with BW-SPH-B, BW-SPH-D,
BW-SPH-E and BW-SPH-F (p < 0.05, Table 6).
Table 6. In vitro dipeptidyl peptidase-IV (DPP-IV) inhibitory and insulin secretory activity of blue
whiting (Micromesistius poutassou) soluble protein hydrolysates (BW-SPHs) pre- and post-simulated
gastrointestinal digestion (GI).
Sample Code DPP-IV Inhibitory ActivityIC50 (mg protein/mL)
Insulin Secretion
(Fold Change Compared to Control)
BW-SPH-A 2.42 ± 0.04 b 4.47 ± 0.27 d
BW-SPH-A_GI 2.49 ± 0.07 AB 4.80 ± 0.18 BC
BW-SPH-B 2.37 ± 0.05 b 6.00 ± 0.25 ab
BW-SPH-B_GI 2.54 ± 0.05 AB* 5.38 ± 0.19 A
BW-SPH-C 2.90 ± 0.07 c 4.66 ± 0.53 cd
BW-SPH-C_GI 2.80 ± 0.04 C 4.96 ± 0.21 AB
BW-SPH-D 2.12 ± 0.03 a 6.31 ± 0.21 ab
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Table 6. Cont.
Sample Code DPP-IV Inhibitory ActivityIC50 (mg protein/mL)
Insulin Secretion
(Fold Change Compared to Control)
BW-SPH-D_GI 2.39 ± 0.07 A* 4.48 ± 0.14 C*
BW-SPH-E 2.46 ± 0.03 b 5.49 ± 0.20 bc
BW-SPH-E_GI 2.63 ± 0.08 B* 4.86 ± 0.10 BC
BW-SPH-F 2.41 ± 0.03 b 6.42 ± 0.30 a
BW-SPH-F_GI 2.56 ± 0.07 AB* 4.68 ± 0.13 BC*
IC50: inhibitory concentration that inhibits recombinant human DPP-IV activity by 50%, mean ± SD (n = 3).
Insulin secretion from clonal pancreatic BRIN-BD11 beta-cells is expressed as fold change compared to control
(buffer/media containing 5.6 mM glucose alone), mean ± S.E.M. (n = 6). Different lower case letters (a,b,c) within
a column indicates a significant difference between BW-SPH samples pre-simulated gastrointestinal digestion at
p < 0.05. Different capital letters (A,B) within a column indicates a significant difference between BW-SPH samples
post-simulated gastrointestinal digestion at p < 0.05. * indicates a significant difference at p < 0.05 between pre-
and post-simulated gastrointestinal digestion values.
2.5. Insulin Secretory Activity
Viability analysis using the MTT assay indicated that none of the samples analysed
were cytotoxic to BRIN-BD11 cells at the dose tested (2.5 mg/mL, Supplementary Figure S2).
All BW-SPHs samples (both pre- and post-SGID) were shown to stimulate the secretion
of insulin from BRIN-BD11 cells (Table 6). Highest activity was seen with BW-SPH-F
where a 6.42-fold increase in insulin secretion from BRIN-BD11 cells above the basal rate
(5.6 mM glucose alone) was observed following incubation with 2.5 mg/mL of the BW-SPH.
However, this activity was significant reduced following SGID with a 4.68-fold increase
above the basal rate observed following incubation with an equivalent concentration of BW-
SPH-F_GI (p < 0.05; Table 6). The insulinotropic activity of BW-SPH-D was also significantly
reduced during SGID with fold changes versus the control of 6.31 ± 0.21 and 4.48 ± 0.14
recorded pre- and post-SGID, respectively. SGID had no significant effect on the insulin
secretory activity of all other BW-SPHs assessed (Table 6).
3. Discussion
The search for new marine-derived biological sources of commercial value is a major
goal for the sustainable utilisation of natural fishery resources, the utilisation of low-
value by-catch and ultimately the economic survival of the fisheries industry worldwide.
Valorisation of low-value fish species using a biorefinery approach, where multiple co-
products arise from the biomass in a single process, represents an innovative strategy to
increase the value of low-value species in addition to reducing the waste associated with
processing side streams [12]. Blue whiting, a low-value underutilised fish species, which is
landed in high volumes in the Northeast Atlantic, is a reservoir of high-value nutritional
and health enhancing components. Blue whiting-derived proteins, in particular protein
hydrolysates which have shown anti-diabetic and appetite control activities in vitro and
in vivo [6–10], offer potential as dietary sources of protein to meet the ever-increasing
global protein demand and as high-value functional peptide ingredients [6]. However, as
previously stated, the reproducible production of products, which are free from marine
associated tastes and odours, at large scale poses many challenges for the marine processing
industry. However, recent advances in innovative technologies and processes used for the
sustainable conversion of fishery resources to a range of high added-value biomaterials
in a biorefinery approach has in part addressed this challenge. However, due to their
predominant marine taste and odour, the oral ingestion of fish protein-derived hydrolysates
generally requires the utilisation of delivery matrices containing specific masking agents
to render these ingredients organoleptically acceptable for consumers. In this study six
BW-SPHs generated from the same source material using different hydrolysis conditions,
in a biorefinery approach at industrial scale, were investigated in terms of their protein
equivalent content, amino acid profile and score, physicochemical and in vitro anti-diabetic
properties and susceptibility to SGID.
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To support normal bodily functions, growth and repair, humans are required to intake
specific quantities of protein on a daily basis, in addition to sufficient provisions of dietary
essential amino acids which are not synthesised within the body. The recommended daily
protein intake for adults is 0.66 g/kg body weight with recommended levels varying
depending on the protein needs of the cohort, e.g., infants, children, adolescents, pregnant
and lactating women [13]. The universally used N:P conversion factor of 6.25 can only
provide an estimate of a sample’s protein content. This non-specific N:P conversion factor
assumes that 1 kg of protein contains 160 g of nitrogen. However, the nitrogen content
of food proteins can vary significantly and is dependent on the amino acid composition,
and more specifically the nitrogen content of the constituent amino acids within the food
protein [14]. Therefore, calculation of sample specific N:P conversion factors is required to
determine the exact protein content of a sample. N:P conversion factors for the six BW-SPHs,
which were calculated based on the amino acid profiles of the test samples, ranged from
5.04 to 5.24 and were similar to those reported for other fish protein hydrolysates [15,16].
Based on these sample specific N:P conversion factors the protein equivalent content of the
BW-SPHs was determined to be 70.37 to 73.60% (w/w). Furthermore, physicochemical data
such as DH, molecular mass distribution, RP-UPLC and free amino profiles demonstrate
that the variation in hydrolysis conditions resulted in the generation of BW-SPHs with
distinctly different characteristics.
In addition to variation in the recommended daily protein intake level, different
population cohorts require different quantities of each essential amino acid and as such
it has been recommended that the protein quality of a food protein be determined based
on three reference amino acid scoring patterns [11]. These include those set for (1) infants
less than 6 months old, (2) children from 6 to 36 months old and (3) children older than
36 months, adolescents and adults [11]. In this study the ratio of each of the essential
amino acids in the six BW-SPHs compared to that of levels outlined in each of the three
reference cohorts were determined, with the lowest ratio being related to the amino acid
score. Protein quality scores, which are evaluated based on the digestibility of the protein
and the bioavailability of the essential amino acids therein, indicate whether a given food
protein meets human dietary requirements for a specific cohort [11]. However, amino acid
score evaluation provides useful information on how the essential amino acid levels in
a protein rate against a reference protein along with information on which amino acid(s)
may be limiting in the test protein sample. The six BW-SPHs studied herein were shown to
contain all essential amino acids, however, when compared to the reference amino acid
profiles [11] varying results were observed. In general, the level of the valine, isoleucine,
leucine, tryptophan and the aromatic amino acids tyrosine and phenylalanine in the six BW-
SPHs, did not meet the essential amino acid requirements for infants from birth to 6 months.
The level of tryptophan in the BW-SPHs was seen to be particularly low compared to the
recommended tryptophan intake levels for this cohort with amino acid scores ranging
from 0.29 and 0.40. Therefore, the BW-SPHs generated herein would not be suitable for
stage 1 infant formula (<6 months) applications [11]. Tryptophan was also identified as
the first limiting amino acid in the 6-month to 3-year cohort, and with the exception of
this amino acid, all other essential amino acids were at levels similar or higher than those
of the recommended reference protein in the 6 month to 3-year cohort. It must be noted
that the tryptophan level in BW-SPH-D at 8.38 mg/g protein was only slightly below the
recommended 8.50 mg/g protein for this cohort [11]. However, it is highly unlikely that
fish protein hydrolysates would be the sole source of protein for this grouping. Blending
of BW-SPHs with other protein sources rich in tryptophan could be an option for the
generation of dietary products for this cohort. Again, the first limiting amino acid in all
BW-SPHs compared to the older children, adolescent, adult amino acid scoring reference
was tryptophan. However, with the exception of BW-SPH-C, the amino acid scores for this
cohort were all above 1, which would indicate that the levels of all essential amino acids in
the other five BW-SPHs met those levels recommended for the older children, adolescent,
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adult grouping. The level of tryptophan in BW-SPH-C at 6.18 mg/g protein, however,
meets the recommended level for adults (6.0 mg/g protein) [11].
Beyond the provision of dietary protein, protein hydrolysates, peptides and free amino
acids can beneficially regulate metabolic functions in the body, including glycaemia [17–19].
T2DM is a chronic metabolic condition characterised by a deficiency in the secretion and/or
function of insulin (i.e., insulin resistance), resulting in high blood glucose levels [20].
The prevalence of T2DM is increasing globally and effective interventions are required
to prevent and manage the condition. Food protein-derived peptides with glycaemic
regulatory properties may have applications in targeted dietary approaches for early-
stage/prediabetic subjects where the use of drug-based treatments is not warranted. They
may also have potential applications in combination with current pharmaceutical treat-
ments thus allowing for a reduction in conventional drug dosage, which in turn could lead
to reduced side-effects and healthcare costs.
The in vitro data presented herein demonstrates that the six BW-SPHs investigated
can inhibit DPP-IV, the ubiquitous enzyme involved in the rapid degradation of the in-
cretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic
polypeptide (GIP) in vivo and directly stimulate the secretion of insulin from pancreatic
β-cells [6]. The most potent DPP-IV inhibitory activity was observed with BW-SPH-D
(IC50: 2.12 ± 0.3 mg protein/mL). The potency values obtained for the six BW-SPHs were
lower than those obtained previously for a BW-SPH generated with the proteolytic en-
zyme preparations Alcalase 2.4 L and Flavourzyme 500 L (IC50: 1.28 ± 0.4 mg /mL) [6].
However, this difference may be due to the origin of the DPP-IV enzyme utilised in both
studies. The present study used human-derived DPP-IV whereas the previous study used
porcine-derived DPP-IV. It has been documented that human-derived DPP-IV is less active
than its porcine-derived equivalent [21,22]. For example, the IC50 value for the reference
DPP-IV inhibitory tripeptide, Ile-Pro-Ile (Diprotin A), was 3.49 ± 0.19 and 5.00 ± 0.03 µM
when using porcine and human-derived DPP-IV, respectively [21,23]. Furthermore, all
hydrolysates were shown to stimulate the secretion of insulin from pancreatic BRIN-BD11
β-cells grown in culture. The highest activity was observed with BW-SPH-F, which me-
diated a 6.42-fold increase in insulin response, when assessed at 2.5 mg/mL, compared
to the basal control (5.6 mM glucose alone). The insulinotropic results obtained herein
were similar and, in some cases, higher than those obtained previously for blue whiting,
boarfish and salmon protein hydrolysates when assessed at an equivalent concentration
under the same conditions [6,21,24,25].
In order for a peptide to exert its activity in vivo it may need to reach the site of action
in an active form. While in vivo studies can ultimately identify this, they are expensive,
time-consuming, technically difficult and require ethical clearance. While in vitro digestion
models have known limitations and cannot mimic the complex dynamics of the digestion
process or the physiological interactions within the host in vivo they can provide infor-
mation on the potential stability and metabolic fate of the active component(s) during
gastrointestinal transit [26]. Physicochemical characterisation data (DH, molecular mass
distribution, RP-UPLC and free amino acid profiles) showed that all six BW-SPHs were
digested during SGID. Analysis of subsamples taken following exposure to pepsin indicate
that little or no digestion occurred during the simulated gastric phase (data not shown).
Therefore, the BW-SPH-derived peptides were mainly degraded by the intestinal enzymes
trypsin, chymotrypsin and/or elastase present in Corolase PP, the enzyme preparation
utilised herein to mimic intestinal digestion. SGID had no effect on the DPP-IV inhibitory
activity exhibited by BW-SPH-A and BW-SPH-C. However, a significant decrease in DPP-IV
inhibitory activity was observed with BW-SPH-B, BW-SPH-D, BW-SPH-E and BW-SPH-F
following SGID (p < 0.05). This would indicate that DPP-IV inhibitory peptides in the
original hydrolysate were degraded and lost activity during the SGID process. The in-
sulinotropic potency of BW-SPH-D and BW-SPH-F was also reduced significantly (p < 0.05)
following SGID. All other hydrolysates showed no significant reduction in insulin secretory
activity following SGID. Interestingly, the DPP-IV inhibitory and insulin secretory activity
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mediated by BW-SPH-C_GI, the hydrolysate which was significantly degraded during
SGID based on differences in DH values pre- and post-SGID, was similar to that prior to
in vitro digestion. It is plausible that a combination of the following occurred: peptides me-
diating activity were not hydrolysed, peptides showing activity pre-SGID were degraded
to fragments with less or more potent activity and fragments exhibiting activity arose from
formerly inert peptides following SGID. While there was a reduction in activity following
SGID with some of the BW-SPHs assessed, all samples still exhibited DPP-IV inhibitory
activity following SGID (IC50 value range: 2.39–2.80 mg protein/mL) and exhibited high
insulin secretory activity with 4.48–5.38-fold changes above the basal control observed.
Therefore, these hydrolysates could potentially beneficially regulate blood glucose level
in vivo through direct stimulation of insulin secretion from pancreatic β-cells or indirectly
through inhibition of DPP-IV, thereby increasing or maintaining the level of circulating
GLP-1 and GIP. However, this needs to be evaluated in human studies.
While the structure-activity relationship of DPP-IV inhibitory and insulin secretory
peptides has not yet been fully elucidated, some structural features which influence their
activity have been identified [21,27,28]. Furthermore, free amino acids such arginine, ty-
rosine and phenylalanine are known to inhibit DPP-IV [29,30] and glutamine, alanine,
arginine, leucine, phenylalanine, valine, isoleucine and lysine are known to be strong
insulin secretagogues [31–34]. However, no correlation was found between the levels of
DPP-IV inhibitory and insulin stimulatory activity and the levels of amino acids both with
known and unknown activity in both the total and free amino acid profiles of each of the
six hydrolysates pre- and post-SGID (data not shown). Furthermore, no correlation was
observed between the changes in the levels of specific free amino acids during SGID and
alterations in DPP-IV inhibitory and insulin secretory activity during in vitro digestion.
Crude protein hydrolysates generated with proteolytic enzymes with broad specificities can
contain hundreds if not thousands of peptides having different sequences, as well as free
amino acids. It is possible that the activity observed is due to the action of different peptides
and amino acids working alone or more likely working synergistically. Further studies are
therefore required to identify the peptides/amino acids that are potentially responsible for
the observed activity through bioassay-driven fractionation of the hydrolysates and confir-
matory studies need to be performed with the synthetic peptides/amino acids identified
or combinations thereof.
4. Materials and Methods
4.1. Materials
Kjeldahl catalyst tablets were from VWR International (Dublin, Ireland). Low ni-
trogen sodium hydroxide (40% (w/v)) and sulphuric acid were from TE Laboratories
Ltd. (Carlow, Ireland) and Lennox Laboratory Supplies Ltd. (Dublin, Ireland), respec-
tively. The enzyme preparations, BC pepsin and Corolase® PP, were kindly provided
by Biocatalysts Ltd. (Cardiff, Wales, UK) and AB Enzymes (Darmstadt, Germany), re-
spectively. Trinitrobenzenesulphonic acid (TNBS) reagent was from Medical Supply Co
Ltd. (Dublin, Ireland). Diprotin-A (IPI: Ile-Pro-Ile) and H-Gly-Pro-7-amino-4-methyl
coumarin (AMC) were purchased from Bachem Feinchemikalien (Bubendorf, Switzerland).
Hank’s buffered saline solution (HBSS 10×), RPMI-1640 culture media, trypsin/EDTA
(10×), penicillin-streptomycin (0.1 g/L) and fetal bovine serum (FBS) were bought from
Gibco Life Technologies Ltd. (Paisley, Strathclyde, UK). Rat insulin standard and radio-
labelled sodium iodide (Na 125I, IMS 100 mCi/mL) were obtained from Novo Industria
(Copenhagen, Denmark) and Perkin Elmer (Buckinghamshire, UK), respectively. The other
reagents, as well as DPP-IV (human recombinant, expressed in Sf 9 cells; ≥4500 units/µg
protein), were purchased from Sigma Chemical Company Ltd. (Wicklow, Ireland).
4.2. Generation of Blue Whiting Soluble Protein Hydrolysates (BW-SPHs)
Six BW-SPH (BW-SPH-A_F) samples were generated at industrial scale from thawed
minced blue whiting according to the parameters provided in Table 4 at BioMarine Ingre-
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dients Ireland Ltd. (Lough Egish Food Park, Castleblaney, Co., Monaghan, Ireland). All
enzyme preparations used were food-grade and of microbial origin. Following hydrolysis,
the enzymes were inactivated at 90 ◦C for 15 min and the bones were separated using a
vibrating sieve. A two-phase centrifugation process was used to separate the water-soluble
fraction (BW-SPH) from the undigested residue. This was followed by ultrafiltration and
dehydration of the soluble phase to approx 50% (w/w) total solids, prior to spray drying.
4.3. Protein and Amino Acid Analysis
The moisture content of the BW-SPHs was determined gravimetrically by weight
loss upon drying for 6 h at 105 ◦C. The nitrogen content was quantified by the procedure
described by Connolly et al. [35]. Nitrogen to protein conversion factors were determined
using the procedure described by Sriperm et al. [36] and employed to estimate the crude
protein equivalent content. The analyses performed herein were performed in triplicate
(n = 3). Total and free amino acid analysis was performed by an external contract supplier.
The amino acid score for each BW-SPH was calculated as: mg of limiting essential
amino acid per g of test protein divided by mg of the same amino acid per g of reference pro-
tein. The reference proteins were based on the amino acid scoring patterns recommended
by the FAO, which were using the reference protein for (1) infants less than 6 months old,
(2) children from 6 to 36 months old and (3) children older than 36 months, adolescents
and adults [11].
4.4. Simulated Gastrointestinal Digestion (SGID)
A modification of the method described by Walsh et al. [37] was used to perform SGID.
In brief, BW-SPHs at a protein equivalent concentration of 2.0% (w/v) were incubated at
37 ◦C and pH 2 for 90 min with pepsin at an E:S of 2.5% (w/w). The pH was then adjusted
to pH 7 with 5N NaOH and further incubated at 37 ◦C for 150 min with 1% (w/w) Corolase
PP. Samples were then heated at 85 ◦C for 15 min, freeze-dried and kept at −20 ◦C until
used.
4.5. Physicochemical Characterisation
The TNBS method described previously by Harnedy et al. [6] was utilsed to estimate
the degree of hydrolysis (DH). The DH was calculated as follows: %DH = 100 × ((AN2
− AN1)/Npb). AN1 refers to the amino nitrogen content of the protein substrate (mg/g
protein)), AN2 refers to the amino nitrogen content of the hydrolysate (mg/g protein) under
investigation and Npb is the nitrogen content of the peptide bonds in the unhydrolysed
protein. Values of 5.6 and 102.3 were used for AN1 and Npb, respectively [38].
Molecular mass distribution and hydrophobicity/hydrophilicity analysis were carried
out by gel permeation-high performance liquid chromatography (GP-HPLC) and RP-UPLC,
respectively, in order to determine the peptide profiles of the test samples [39,40]. These
analyses were performed in triplicate (n = 3).
4.6. In Vitro DPP-IV Inhibitory Activity Assessment
DPP-IV inhibitory activity was ascertained as described previously [23]. In short, 50 µL
of the substrate (200 µM H-Gly-Pro-AMC) was combined with 10 µL of test hydrolysate
and 30 µL buffer (0.02 M Tris-HCl buffer, pH 8.0 containing 0.10 M NaCl and 1 mM
EDTA) and preheated to 37 ◦C (5 min) in a plate reader (BioTek Synergy HT, Winooski,
VT, USA). Then, 10 µL of DPP-IV was added at 8 mU/mL and the fluorescence ouput
was monitored at excitation and emission wavelengths of 360 and 460 nm, respectively
for 30 min. The synthetic peptide IPI (Diprotin A) was employed as a positive control at a
final concnetration of 5 µM. The activity results which were performed in triplicate were
expressed as IC50 values (inhibitory concentration (mg protein/mL) that inhibits DPP-IV
by 50%).
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4.7. Insulin Secretion Studies in Clonal Pancreatic Cells
The insulinotropic effects of samples were measured in vitro using clonal pancreatic
BRIN-BD11 cells which are a hybrid cell line formed following the electrofusion of immortal
RINm5F cells with a primary culture of New England Deaconess Hospital rat pancreatic
islet cells [41]. The cells were cultured at 37 ◦C in an atmosphere of 5% CO2 and 95% air
in RPMI-1640 tissue culture medium containing 10% (v/v) fetal calf serum, antibiotics
(100 U/mL penicillin, 0.1 mg/mL streptomycin) and 11.1 mM glucose as previously
described [41].
In the first instance, cellular viability of test samples (2.5 mg/mL) on BRIN-BD11
cells was determined using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) assay. In brief, test samples prepared in Krebs Ringer bicarbonate buffer (KRBB)
supplemented with 5.6 mM glucose were incubated for 20 min at 37 ◦C. KRBB was removed
and Hank’s balanced salt solution (HBSS) was used to wash the cells. RPMI media (100 µL)
was then added followed by 20 µL of MTT solution (5 mg/mL stock). Following a 2 h
incubation in a modified atmosphere (95% O2, 5% CO2) tissue culture incubator at 37 ◦C
the MTT/growth media was aspirated and cells were washed with HBSS. A volume of
100 µL of DMSO was used to dissolve the developed formazan crystals and the plate was
agitated at room temperature for 5 min. The absorbance was read at 570 nm.
To determine the insulin secretory effects the BRIN-BD11 cells (1.5 × 105 cells/well)
were incubated for 20 min with the test samples in the presence of 5.6 mM glucose at 37 ◦C.
Following incubation, 900 µL of supernatant was withdrawn and frozen at −20 ◦C until
required. The insulin content was quantified using a dextran-coated charcoal radioim-
munoassay (RIA), utilising crystalline rat insulin as a standard and guinea-pig anti-porcine
antiserum (1:30,000 dilution) and 125I-bovine standard (10,000 cpm) [42].
4.8. Statistical Analysis
The software programs SPSS (Version 26, IBM Inc., Chicago, IL, USA) and GraphPad
Prism version 5.0 (GraphPad Software Inc., San Diego, CA, USA) were used to perform
statistical analyses on the data. Data was expressed as mean ± SD for all data except
insulin secretion data which was expressed as mean ± SEM. One-way analysis of variance
(ANOVA) was used to compare all values which was followed by Tukey’s and Games–
Howell post hoc tests. Values before and after SGID were compared using students t-tests.
5. Conclusions
The results presented herein indicate that protein hydrolysates generated from blue
whiting, a low-value underutilised fish species, provide potential as a source of high-quality
protein for human nutrition. The variation in hydrolysis conditions employed led to the
generation of BW-SPHs with distinctly different characteristics. The BW-SPHs were shown
to mediate promising in vitro DPP-IV inhibitory and insulin secretory activity. Whilst
the hydrolysates were degraded during SGID the resultant digests mediated high in vitro
anti-diabetic activity which would indicate that they may have potential as anti-diabetic
agents in vivo. However, the efficacy of the peptides needs to be confirmed in human
studies before such claims could be made. Peptide identification and confirmatory studies
are also required in order to identify the peptide(s) and amino acids responsible for the
observed activity. Finally, the sustainable conversion of low-value marine resources to high-
value proteinaceous ingredients such as those observed herein can help improve the fish
processing industry’s financial security whilst also enhancing environmental sustainability.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/md19070383/s1, Figure S1: Reverse phase ultra-performance liquid chromatography profiles
of blue whiting (Micromesistius poutassou) soluble protein hydrolysates (BW-SPH) pre- and post-
simulated gastrointestinal digestion (SGID) and Figure S2: Effect of (A) blue whiting (Micromesistius
poutassou) soluble protein hydrolysates (BW-SPH) and (B) their simulated gastrointestinal digestion
(SGID) samples on cellular viability of BRIN-BD11 cells, measured using the MTT assay.
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